Dentsply Sirona (XRAY) Q3 earnings report preview: what to look for

Dentsply Sirona (XRAY) is set to report Q3 earnings. Last quarter, it beat revenue and EPS estimates, with revenue at $898M, down 4.1% YoY. Analysts expect Q3 revenue to decline 4.9% YoY. The stock is up 14.1% over the last month, with an average price target of $12.40.

Original reporting
Published Nov 4, 2026, 3:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dentsply Sirona (XRAY) Q3 earnings report preview: what to look for — source image
Decision brief

The 30-second read

$XRAYNeutralMed
01

Why it matters

For traders, the actionable element is the upcoming earnings timing plus the direction of consensus (revenue expected to decline YoY) and the note that analysts have largely reconfirmed estimates.

02

Market read

XRAY is heading into earnings with consensus expecting a modest YoY revenue decline, while the stock has already rallied over the past month.

03

What to watch

The preview does not specify margin, cash flow, or guidance details for this quarter, which are often the true drivers of post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: ahead of Thursday afternoon Q3 earnings release

Background

The article is a pre-earnings preview for Dentsply Sirona’s Q3 report, referencing last quarter’s revenue/EPS beat and current consensus expectations.

Company-level read

Ticker impact

$XRAYNeutralMedium confidence
Context

Dentsply Sirona is set to report Q3 earnings this Thursday, with the article citing expected revenue decline and recent estimate reconfirmations.

Expected impact

Likely limited upside unless revenue/EPS beat meaningfully versus the cited expectations, since the piece emphasizes consensus stability and a prior revenue-estimate track record.

Evidence & confidence

The article provides a scheduled earnings catalyst and consensus direction (revenue down ~4.9% YoY) but does not introduce new guidance, prints, or surprises beyond preview-level context.

Market effects

Peers’ recent results (Henry Schein, Align Technology) are used as read-through, implying the healthcare equipment and supplies tape may influence XRAY’s earnings expectations.

No specific regional impact beyond US-listed healthcare equipment sentiment.

Limited, as the piece is US-focused and uses peer results as directional context rather than global macro drivers.

Counterpoint

If XRAY’s revenue decline is worse than the cited ~4.9% expectation, the stock’s prior month outperformance could make it vulnerable to a sharper post-earnings reset.

Key entities

  • Dentsply Sirona

    NASDAQ-listed dental products company scheduled to report Q3 earnings Thursday afternoon.

  • Henry Schein

    Peer cited as having delivered YoY revenue growth in its Q3 results.

  • Align Technology

    Peer cited as having reported revenues up YoY and topping estimates.

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.